HIPRA COVID-19 vaccine clinical trials
How each study uses HIPRA COVID-19 vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- COVID-19 Vaccine HIPRA
- 2
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Hipra Scientific, S.L.U (4)
Studies
Open first, then newest update. How each study uses HIPRA COVID-19 vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.CompletedPhase 2Hipra Scientific, S.L.UNCT05305573Written as COVID-19 Vaccine HIPRA 40 ug/doseHow we know
- A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.CompletedPhase 2/3Hipra Scientific, S.L.UNCT05303402Written as PHH-1VHow we know
- Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)CompletedPhase 2Hipra Scientific, S.L.UNCT05142514Written as COVID-19 Vaccine HIPRAHow we know
- Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.CompletedPhase 2Hipra Scientific, S.L.UNCT05142553Written as COVID-19 Vaccine HIPRAHow we know
Codes
What other systems call HIPRA COVID-19 vaccine · ClinicalTrials.gg INT001690
- MeSH (NLM) C000718744HIPRA COVID-19 vaccineOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718744 | HIPRA COVID-19 vaccine | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.